Agreements reached under this partnership
Business alliance- 1
Provision of specialized expertise on boron drugs for BNCT
- 2
Advice on regulatory affairs and clinical development, as appropriate to the research content
- 3
Advice on protocol preparation
- 4
Cooperation in the provision of drugs
- 5
Sharing of safety information
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on the Company's results for the fiscal year ending March 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Okayama University, a national university corporation |
| Type of alliance | Business alliance |
| Details of the alliance | Provision of specialized expertise on boron drugs for BNCT, Advice on regulatory affairs and clinical development, as appropriate to the research content, Advice on protocol preparation, Cooperation in the provision of drugs, Sharing of safety information |
| Contract Date | 27 July 2026 |
| Alliance start date | Research and development to commence on 1 April 2026 (research and development period) |
| Impact on Business Performance | The impact of this matter on the Company's results for the fiscal year ending March 2027 is expected to be immaterial. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To prepare a protocol and establish a research structure for the future implementation of a B-NIT investigator-initiated clinical trial under the research and development project selected by AMED.